Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer

This study is testing a combination of four drugs — capecitabine, oxaliplatin (together called CapeOX), sintilimab (an immunotherapy), and bevacizumab (a drug that blocks tumor blood supply) — as a first-line treatment for people with advanced or metastatic stomach or gastroesophageal junction cancer. **You may be eligible if...** - You are between 18 and 70 years old - You have been confirmed by biopsy to have stomach or gastroesophageal junction cancer (adenocarcinoma) - Your cancer has spread or come back and cannot be surgically removed - You have not yet received chemotherapy for your advanced cancer (or finished adjuvant chemo at least 6 months ago) - Your expected survival is more than 3 months - Your organ function (liver, kidneys, blood) is adequate **You may NOT be eligible if...** - You have already received chemotherapy for metastatic disease - You have serious heart, liver, or lung conditions - You are pregnant or breastfeeding - Your general health is too poor for combination chemotherapy Talk to your doctor to see if this trial is right for you.